A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

Trial Profile

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ENDURANCE-2
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Jun 2018 Results of pooled data from 10 studies (SURVEYOR-I, -II, MAGELLAN-I, ENDURANCE-1, -2, -3, -4, EXPEDITION-1, -2 and -4; n=2522 ),were presented at the Digestive Disease Week 2018.
    • 14 Apr 2018 Results of an integrated analysis of 10 studies (SURVEYOR-I, -II, MAGELLAN-I, ENDURANCE-1, -2, -3, -4, EXPEDITION-1, -2 and -4; n=789) assessing efficacy and safety in patients with psychiatric disorders, presented at The International Liver Congress 2018
    • 15 Mar 2018 Results (n=2041) of integrated efficacy analysis from EXPEDITION-2, EXPEDITION-4, ENDURANCE 1, 2, 3 and 4, SURVEYOR-I Part 2, SURVEYOR-II Parts 1 and 2, and SURVEYOR-II Part 4 studies published in the Journal of Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top